Stocks and Investing Stocks and Investing
Thu, June 21, 2018
Wed, June 20, 2018

Matthew Harrison Maintained (SRPT) at Hold with Increased Target to $163 on, Jun 20th, 2018


Published on 2024-10-26 06:15:41 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Hold with Increased Target from $91 to $163 on, Jun 20th, 2018.

Matthew has made no other calls on SRPT in the last 4 months.



There are 6 other peers that have a rating on SRPT. Out of the 6 peers that are also analyzing SRPT, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Hartaj Singh of "Oppenheimer" Downgraded from Buy to Hold on, Friday, May 4th, 2018


These are the ratings of the 5 analyists that currently disagree with Matthew


  • Debjit Chattopadhyay of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $267 on, Tuesday, June 19th, 2018
  • Yun Zhong of "BTIG" Initiated at Strong Buy and Held Target at $120 on, Friday, June 15th, 2018
  • Gena Wang of "Barclays" Upgraded from Hold to Buy on, Friday, May 11th, 2018
  • Alethia Young of "Credit Suisse" Maintained at Buy with Decreased Target to $92 on, Friday, May 4th, 2018
  • Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $95 on, Wednesday, March 14th, 2018
Contributing Sources